CORCEPT THERAPEUTICS INC Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CORCEPT THERAPEUTICS INC (CORT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00.
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $2.87M.
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $5.75M, a 1834.34% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $297.00K, a 89.45% decline from fiscal 2022.
- CORCEPT THERAPEUTICS INC right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $2.82M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-29 | $2.87M 10-Q · filed 2026-07-29 | $2.87M derived: sum of 3 quarters · filed 2026-07-29 | $2.87M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $2.87M 10-Q · filed 2026-04-30 | $2.87M derived: sum of 2 quarters · filed 2026-04-30 | $2.87M derived: sum of 3 quarters · filed 2026-04-30 | $2.87M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | $0.00 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-07-29 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | $0.00 derived: sum of 3 quarters · filed 2026-07-29 | $0.00 derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | $5.75M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $5.75M derived: sum of 3 quarters · filed 2026-02-24 | $5.75M 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | $5.75M derived: sum of 2 quarters · filed 2025-11-04 | $5.75M 10-Q · filed 2025-11-04 | $6.04M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $5.75M 10-Q · filed 2025-07-31 | $5.75M 10-Q · filed 2025-07-31 | $6.04M derived: sum of 3 quarters · filed 2026-02-24 | $6.34M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $297.00K 10-Q · filed 2025-05-05 | $297.00K derived: sum of 2 quarters · filed 2026-02-24 | $594.00K derived: sum of 3 quarters · filed 2026-02-24 | $891.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $297.00K derived: sum of 2 quarters · filed 2026-02-24 | $594.00K derived: sum of 3 quarters · filed 2026-02-24 | $297.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | $297.00K 10-Q · filed 2024-10-30 | $594.00K derived: sum of 2 quarters · filed 2024-10-30 | $297.00K 10-Q · filed 2024-10-30 | $594.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $297.00K 10-Q · filed 2024-07-29 | $297.00K 10-Q · filed 2024-07-29 | $297.00K derived: sum of 3 quarters · filed 2025-02-26 | $297.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $2.82M 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $2.82M 10-Q · filed 2023-11-01 | $2.82M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $2.82M 10-Q · filed 2023-08-02 | $2.82M derived: sum of 3 quarters · filed 2023-08-02 | $2.82M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $2.82M 10-Q · filed 2023-05-03 | $2.82M derived: sum of 2 quarters · filed 2023-05-03 | $2.82M derived: sum of 3 quarters · filed 2023-05-03 | $2.82M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2022-08-04 | $0.00 derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | $775.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $775.00K derived: sum of 3 quarters · filed 2022-02-15 | $775.00K 10-K · filed 2022-02-15 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-03 | $775.00K derived: sum of 2 quarters · filed 2020-11-03 | $775.00K 10-Q · filed 2020-11-03 | $3.81M derived: sum of 4 quarters · filed 2021-02-23 |
| 2020-06-30 | $775.00K 10-Q · filed 2020-08-04 | $775.00K derived: sum of 2 quarters · filed 2020-08-04 | $3.81M derived: sum of 3 quarters · filed 2021-02-23 | $3.81M derived: sum of 4 quarters · filed 2021-02-23 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-04 | $3.04M derived: sum of 2 quarters · filed 2021-02-23 | $3.04M derived: sum of 3 quarters · filed 2021-02-23 | $3.04M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-12-31 | $3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $3.04M derived: sum of 2 quarters · filed 2021-02-23 | $3.04M derived: sum of 3 quarters · filed 2021-02-23 | $4.91M 10-K · filed 2021-02-23 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-03 | $0.00 derived: sum of 2 quarters · filed 2020-11-03 | $1.88M 10-Q · filed 2020-11-03 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | $1.88M derived: sum of 2 quarters · filed 2020-08-04 | ||
| 2019-03-31 | $1.88M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |